List of Excipients in Branded Drug PIMECROLIMUS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceuticals	PIMECROLIMUS	pimecrolimus	68682-112	BENZYL ALCOHOL
Oceanside Pharmaceuticals	PIMECROLIMUS	pimecrolimus	68682-112	CETYL ALCOHOL
Oceanside Pharmaceuticals	PIMECROLIMUS	pimecrolimus	68682-112	CITRIC ACID MONOHYDRATE

Generic Drugs Containing PIMECROLIMUS

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	pimecrolimus	0591-2944	ANHYDROUS CITRIC ACID
Actavis Pharma Inc	pimecrolimus	0591-2944	BENZYL ALCOHOL
Actavis Pharma Inc	pimecrolimus	0591-2944	CETOSTEARYL ALCOHOL

What are the Most Frequently-Used Excipients in PIMECROLIMUS?

# Of NDCs	Excipient
3	ANHYDROUS CITRIC ACID
3	BENZYL ALCOHOL
2	CETOSTEARYL ALCOHOL

Last updated: August 9, 2026

Executive summary: Pimecrolimus is a mature topical calcineurin inhibitor with limited remaining molecule-level exclusivity and an established commercial reference product, Elidel 1% cream. The main opportunity is formulation differentiation rather than basic active-ingredient protection. Excipients can improve pimecrolimus solubilization, skin deposition, spreadability, preservative tolerance, packaging compatibility, and patient adherence. The strongest near-term opportunities are generic or authorized-generic cream products, low-irritation formulations, preservative-reduced systems, and alternative semisolid delivery formats that can satisfy FDA topical equivalence requirements.

Pimecrolimus Excipient Strategy and Commercial Opportunities

What is the commercial status of pimecrolimus?

Pimecrolimus is a small-molecule ascomycin macrolactam used topically for mild-to-moderate atopic dermatitis. The U.S. reference product, Elidel Cream 1%, was approved by the FDA in December 2001 under NDA 021302. It is indicated for patients aged 2 years and older when topical calcineurin inhibition is appropriate and conventional topical treatments are inadvisable or ineffective. The product carries a boxed warning concerning potential malignancy risk and is recommended for short-term or intermittent use.[1]

Pimecrolimus has no biosimilar pathway because it is a chemically synthesized small molecule. Competition is based on abbreviated new drug applications, national generic procedures, or full applications for materially different dosage forms.

Commercial factor	Pimecrolimus position
Reference product	Elidel 1% cream
Active ingredient	Pimecrolimus
Route	Topical dermal
Strength	1%
Therapeutic category	Topical calcineurin inhibitor
Primary indication	Atopic dermatitis
U.S. approval	2001
Regulatory competition	Generic or full topical application
Biosimilar exposure	None
Main formulation challenge	Delivering a lipophilic active in a stable, cosmetically acceptable cream
Main IP opportunity	Formulation, delivery, manufacturing, and device differentiation

The market is constrained by topical corticosteroids, tacrolimus ointment, crisaborole, ruxolitinib cream, and newer systemic or biologic atopic dermatitis therapies. Pimecrolimus remains commercially relevant where clinicians seek a nonsteroidal topical option, particularly for sensitive areas and intermittent treatment.

What excipients are used in Elidel cream?

The U.S. Elidel label identifies a conventional oil-in-water cream system containing the following inactive ingredients:[1]

Excipient	Likely formulation function
Benzyl alcohol	Preservative and solvent
Cetyl alcohol	Consistency agent and emollient
Citric acid, anhydrous	pH adjustment and buffering
Mono- and diglycerides	Emulsification and emollience
Oleyl alcohol	Emollient and solvent contribution
Propylene glycol	Humectant, cosolvent, and penetration-modifying excipient
Sodium cetostearyl sulfate	Emulsifier and surfactant
Stearyl alcohol	Thickener, emollient, and structural stabilizer
Triglycerides	Oil-phase vehicle and emollient
Purified water	Continuous aqueous phase

The reference formulation uses a mixed fatty alcohol, glyceride, surfactant, glycol, and triglyceride system. That architecture is commercially important because pimecrolimus is highly lipophilic and has limited aqueous solubility. Formulators must control the active’s distribution between the oil phase, interfacial region, and skin surface.

The product is described as a white to off-white homogeneous cream. A generic formulation that duplicates the active concentration but changes the microstructure may produce different release, skin uptake, irritation, and stability results.

How should excipients be selected for pimecrolimus?

Excipient selection should begin with the target product profile rather than with a simple Q1/Q2 copying exercise. The key objectives are chemical stability, physical stability, dermal release, acceptable sensory properties, and controlled skin delivery.

Solubilization and drug distribution

Pimecrolimus should be assessed in:

• Medium-chain and long-chain triglycerides
• Fatty alcohol systems
• Propylene glycol and other pharmaceutically accepted glycols
• Mixed glycerides
• Emulsifier-rich interfacial phases
• Lipid-based solvents and co-solvent combinations

The formulation should avoid uncontrolled crystallization during storage. A system that initially dissolves pimecrolimus can later produce crystals after water loss, temperature cycling, or changes in the internal phase. Polarized-light microscopy, differential scanning calorimetry, X-ray diffraction, and long-term stability testing are useful for detecting active recrystallization.

Emulsion structure

The reference product is a cream, but “cream” does not define its internal microstructure. The developer should characterize:

• Droplet-size distribution
• Continuous-phase viscosity
• Yield stress
• Interfacial composition
• Active partitioning
• Water activity
• pH
• Spreadability
• Rub-in time
• Residual greasiness

These properties influence patient use and in vitro release. A lower-viscosity formulation may improve spreadability but can increase phase separation risk or alter the release rate. A highly structured formulation may improve stability while reducing release from the vehicle.

Skin tolerability

Pimecrolimus is applied to inflamed or barrier-impaired skin. Excipients with known irritation or sensitization potential require careful evaluation. Benzyl alcohol and propylene glycol are useful but can contribute to irritation in susceptible populations. Surfactant load, residual acidity or alkalinity, and fragrance-related components should be minimized.

Potential commercial positioning includes:

• Preservative-reduced or preservative-free packaging
• Lower-irritation systems for facial and intertriginous use
• Reduced sting on application
• Lower residue and improved cosmetic elegance
• Formulations compatible with pediatric application

A preservative-free product would require packaging and microbiological controls that compensate for the loss of benzyl alcohol. Airless pumps, unit-dose packs, and laminated tubes may reduce repeated contamination.

What formulations are protected or commercially available for pimecrolimus?

The established dosage form is a 1% topical cream. Commercial formulation opportunities include:

Formulation concept	Commercial rationale	Main development barrier
Generic cream	Lowest regulatory and technical risk	Demonstrating topical equivalence and competing on price
Low-irritation cream	Differentiates on tolerability	Clinical or comparative irritation support
Preservative-free cream	Addresses sensitive-skin positioning	Microbiological protection and packaging
Lotion	Improves use on large or hairy areas	Maintaining dose uniformity and dermal delivery
Gel	Potentially improves sensory profile	Solubilization, drying, and irritation
Foam	Fast application and low residue	Propellant, manufacturing, and device complexity
Ointment or lipid gel	Higher occlusion and barrier support	Altered penetration and potential safety profile
Spray or metered pump	Convenient application	Dose uniformity and regulatory classification
Anhydrous system	Reduced hydrolysis and microbial risk	Crystallization and skin feel
Emulsion with barrier lipids	Adds moisturization positioning	Increased formulation complexity and equivalence risk

A formulation that changes the dosage form, excipient system, delivery device, or concentration may fall outside the simplest ANDA strategy. A 1% cream with the same active ingredient and a comparable qualitative and quantitative excipient profile is generally the most direct generic route. A materially different product may require a 505(b)(2) application or an equivalent non-U.S. regulatory pathway, depending on the jurisdiction and the proposed claims.

What FDA regulatory requirements apply to generic pimecrolimus cream?

FDA topical products must demonstrate that the proposed product is equivalent to the reference product in the dimensions relevant to topical performance. For a conventional generic cream, the development program typically addresses:

1. Pharmaceutical equivalence, including strength, dosage form, route, and active ingredient.
2. Inactive ingredient acceptability under FDA requirements.
3. Comparative physicochemical characterization.
4. In vitro release testing.
5. In vitro permeation testing where relevant.
6. Microbiological quality and preservative effectiveness.
7. Stability and packaging compatibility.
8. Comparative irritation or sensitization data when required.
9. Bioequivalence requirements specified in the product-specific guidance or FDA review framework.

FDA’s guidance for topical dermatological products identifies formulation sameness, Q1/Q2 characterization, rheology, globule size, pH, and in vitro release as important development considerations.[2] The FDA Inactive Ingredient Database provides precedent for excipient use, route, dosage form, and maximum potency, but it does not by itself establish equivalence or commercial differentiation.[3]

The highest-value excipient work is therefore analytical. A developer should link each excipient change to a measurable critical quality attribute rather than relying on ingredient matching alone.

When did pimecrolimus lose exclusivity?

Pimecrolimus is a mature product. The original U.S. regulatory exclusivity period expired years ago, and the core composition-of-matter and product-related patent barriers have reached or passed their ordinary statutory terms. Current commercial competition is therefore driven by formulation execution, manufacturing cost, regulatory timing, brand recognition, and market access.

Historical U.S. patent records include patents directed to ascomycin derivatives and pimecrolimus-related subject matter. Patent term calculations depend on priority claims, filing dates, patent-term adjustment, terminal disclaimers, and any patent-term extension. The relevant commercial conclusion is that pimecrolimus is no longer protected by a live, broad composition-of-matter monopoly comparable to a newly launched small molecule.

What is the Orange Book status of pimecrolimus?

Elidel was listed in the FDA Orange Book as the reference product for pimecrolimus cream. Orange Book status is relevant to ANDA applicants because listed patents may require Paragraph IV certification, a Section viii statement, or a certification that the patent has expired. For a mature product, the principal Orange Book risk generally shifts from core patent blocking to residual listed patents, pediatric exclusivity history, labeling restrictions, and product-specific FDA requirements.[4]

A live regulatory review should verify the current listing and any remaining patent entries before an ANDA filing. The strategic point is that pimecrolimus does not present the patent density associated with recently approved dermatology products.

Which companies are challenging pimecrolimus exclusivity?

Generic competition has historically included major dermatology and generic manufacturers, including Perrigo, Taro, Teva, Fougera, and other suppliers active in topical semisolid products. The precise set of approved applicants changes over time and differs by market.

The competitive field divides into four groups:

• Large generic companies with established dermatology manufacturing.
• Contract manufacturers offering cream development and filling.
• Branded dermatology companies seeking lifecycle extensions.
• Specialty companies developing alternative delivery systems.

A new entrant would compete against established scale advantages in emulsification, tube filling, quality testing, and payer contracting. A differentiated excipient system is most valuable when it supports a defensible claim, a better patient experience, or a more efficient regulatory pathway.

What patent litigation and Paragraph IV risks affect pimecrolimus?

Pimecrolimus has lower litigation risk than recently launched products because the central exclusivity period has passed. Potential disputes may still arise from:

• Residual Orange Book patents
• Method-of-use claims
• Formulation or delivery-device claims
• Manufacturing-process patents
• Trade-secret claims concerning emulsion processing
• Labeling and carve-out disputes

Paragraph IV exposure is most relevant if a listed patent remains active when an ANDA is filed. A Paragraph IV certification can trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval under the Hatch-Waxman framework. For pimecrolimus, the likely value of a Paragraph IV strategy depends on the specific current Orange Book entries rather than on the historical existence of Elidel patents.

There is no comparable biosimilar litigation pathway. The product is not a biologic, and formulation claims cannot create biologic-style interchangeability barriers.

How strong is the pimecrolimus patent estate?

The core patent estate is weak relative to a recently launched drug. Its principal assets are historical composition, use, formulation, and process patents, many of which have reached their ordinary expiration dates.

The remaining commercial protection is more likely to come from:

• Know-how on active dispersion and emulsion processing
• Manufacturing controls that reduce crystallization
• Device and packaging design
• Specific excipient combinations
• New dosage forms
• Combination products
• New indications supported by clinical data

A new patent directed only to a conventional pimecrolimus cream with routine excipients would face meaningful novelty and obviousness risk. Stronger patent positions may require a defined microstructure, a demonstrated release or deposition advantage, a clinically relevant tolerability result, or a non-obvious manufacturing process.

What licensing deals and commercial partnerships are available?

Pimecrolimus offers limited value as a standalone license for the original molecule. Licensing opportunities are more credible in three areas:

Formulation licensing

A company with a validated low-irritation, preservative-free, anhydrous, or alternative semisolid platform could license the technology to generic or specialty dermatology manufacturers.

Regional commercialization

Regional partners may have value where Elidel access, generic penetration, or dermatology sales infrastructure differs from the United States. The deal structure could combine formulation rights with supply, territory, or minimum-volume commitments.

Contract development and manufacturing

CDMOs with topical capabilities can monetize pimecrolimus through development fees, analytical packages, scale-up, and commercial supply. The most valuable capabilities are sterile or low-bioburden processing where required, high-shear emulsification, controlled cooling, tube filling, and validated in vitro release testing.

No molecule-specific licensing economics should be assumed from historical Elidel commercialization. The commercial case depends on the target country, dosage form, reimbursement environment, and whether the partner receives a differentiated product or only a commodity generic.

What generic launch scenarios exist for pimecrolimus?

Low-cost 1% cream

This is the most direct launch scenario. The product copies the reference dosage form and competes through manufacturing efficiency, pharmacy contracting, and reliable supply. Margins are likely to compress as additional suppliers enter.

Premium generic with improved tolerability

A formulation that reduces sting, residue, or greasiness could support a higher price if the benefit is clinically or commercially credible. The company would need comparative irritation, usability, or adherence evidence.

Pediatric and sensitive-skin positioning

The approved age range begins at 2 years. A formulation optimized for pediatric use could improve acceptance, but promotional claims must remain within the approved label unless supported by a new regulatory submission.

New dosage form

A lotion, foam, gel, or pump product could target patients who dislike conventional cream. This route has higher development and regulatory cost but creates more defensible formulation IP.

Combination or barrier-repair product

A pimecrolimus product combined with moisturization or barrier-support positioning could compete in a broader atopic dermatitis regimen. Combination claims create regulatory, safety, and patent complexity.

How does pimecrolimus compare with tacrolimus and newer competitors?

Product	Active	Dosage forms	Key competitive position
Elidel	Pimecrolimus	1% cream	Nonsteroidal topical calcineurin inhibitor
Protopic	Tacrolimus	0.03% and 0.1% ointments	Established calcineurin inhibitor with stronger occlusive vehicle
Eucrisa	Crisaborole	2% ointment	Nonsteroidal PDE-4 inhibitor
Opzelura	Ruxolitinib	1.5% cream	Topical JAK inhibitor with broader commercial momentum
Dupixent	Dupilumab	Injectable biologic	Systemic biologic option for moderate-to-severe disease

Pimecrolimus has an excipient-driven advantage when the target is a light, cosmetically acceptable cream. Tacrolimus is typically associated with an ointment vehicle, while newer products compete through mechanism, indication breadth, or clinical positioning. The commercial risk is that a better cream vehicle alone may not overcome a weaker reimbursement position or lower prescriber awareness.

What geographic opportunities exist for pimecrolimus?

The strongest geographic opportunities are markets where:

• Generic substitution is permitted.
• Atopic dermatitis prevalence is rising.
• Topical calcineurin inhibitors are reimbursed.
• Local dermatology distribution is fragmented.
• Existing products have limited dosage-form choice.
• Regulatory pathways recognize a reference cream with reduced clinical requirements.

The United States offers a defined ANDA pathway but intense generic competition. Europe and other regulated markets may support decentralized or national generic filings, subject to local requirements for topical equivalence. Emerging markets may offer faster commercial access but lower pricing and greater reliance on local partners.

What manufacturing and IP barriers matter most?

The main manufacturing barriers are process consistency and release control. Pimecrolimus cream production must manage:

• Uniform active distribution
• Emulsion droplet size
• Cooling rate
• Viscosity
• Air incorporation
• Filling accuracy
• Tube and closure compatibility
• Microbial quality
• Active crystallization during storage

The most defensible manufacturing know-how may involve order of addition, shear profile, temperature control, active pre-dissolution, and cooling conditions. These parameters can affect the final product even when the ingredient list appears similar.

Key Takeaways

• Pimecrolimus is a mature topical small molecule with no biosimilar pathway.
• Elidel 1% cream remains the principal reference formulation.
• The reference excipient system uses benzyl alcohol, propylene glycol, fatty alcohols, glycerides, triglycerides, sodium cetostearyl sulfate, citric acid, and water.
• The main formulation risks are poor aqueous solubility, crystallization, dermal irritation, phase instability, and altered release.
• The lowest-risk commercial strategy is a 1% generic cream with close Q1/Q2 and microstructural alignment.
• Higher-value opportunities include preservative-free systems, low-irritation creams, improved sensory performance, pumps, lotions, gels, and foams.
• Core composition-of-matter exclusivity is no longer the main barrier.
• Formulation patents require more than routine excipient substitution. They should claim a defined technical effect, microstructure, process, or clinically meaningful performance advantage.
• Paragraph IV risk depends on current Orange Book entries, not historical Elidel patent activity.
• The strongest commercial differentiation will come from formulation performance, regulatory execution, manufacturing reliability, and market access.

FAQs

Can pimecrolimus be formulated as an ointment instead of a cream?

Yes, but an ointment would change occlusivity, skin penetration, sensory properties, and potentially the regulatory pathway. It should be treated as a new formulation strategy rather than a routine generic substitution.

Is benzyl alcohol necessary in every pimecrolimus cream?

No. It is used in the reference formulation, but alternative preservation and packaging systems may be possible if they meet stability, microbiological, tolerability, and regulatory requirements.

Which excipient is most important for pimecrolimus solubilization?

No single excipient determines performance. Propylene glycol, triglycerides, mixed glycerides, fatty alcohols, and the emulsion interface can collectively control pimecrolimus distribution and release.

Can a pimecrolimus foam receive separate patent protection?

Potentially. A foam may support claims covering composition, propellant system, manufacturing process, device, dose delivery, or skin-deposition performance. Patent strength would depend on novelty, non-obviousness, and demonstrated technical advantages.

Is pimecrolimus suitable for an over-the-counter switch?

The current U.S. product is prescription-only and carries a boxed warning. An OTC switch would require FDA review of consumer labeling, safe self-selection, duration of use, age restrictions, and the risk profile of nonprescription use.

References

1. U.S. Food and Drug Administration. (2024). Elidel (pimecrolimus) cream, 1%: Prescribing information.
2. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Comparative analyses and related comparative use human factors studies for a drug-device combination product submitted in an ANDA.
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.